ACADIA Pharmaceuticals Inc. (ACAD)

25.70
NASDAQ : Health Technology
Prev Close 26.15
Day Low/High 25.54 / 26.10
52 Wk Low/High 12.77 / 28.67
Avg Volume 981.30K
Exchange NASDAQ
Shares Outstanding 144.17M
Market Cap 3.77B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Small-Cap Friday: ACADIA Pharmaceuticals

Small-Cap Friday: ACADIA Pharmaceuticals

I like the biopharma's risk/reward on potential sales of Nuplazid.

My Takeaways and Observations

A win for the bulls. I outlined my cautious view in my opener.  I sold a number of longs and reduced my long side today.   I sold my biotech basket for a good two-and-a-half-week gain.  I reduced my bank longs from large to between small and medium ...

Selling Biotechs for Some Nice Gains

I'm reducing the size of my biotech basket by selling across the board following some very large gains. In fact, I expect to completely eliminate my holdings if we see any further increases. Today's gains have been truly breathtaking. We've seen 5% ...

Biotech Goes From Goat to Hero

Several members in my new biotech basket have continued to make notable upside moves throughout the recent rally, including today. Winners include Acadia Pharmaceuticals (ACAD), Aerie Pharmaceuticals (AERI), Cempra (CEMP), Intrexon (XON), Portola Ph...

My Takeaways and Observations

If I had to guess, today's sharp rally was a function of monthly inflows, technical breakouts and programs. But it is only a guess. However, you will watch in the business media all the talking heads who liked yesterday's market and purchased opport...

My Takeaways and Observations

I started the day giving my bona fide and unadulterated and honest view of Berkshire Hathaway (BRK.B) in a two-part opening missive, which is here and here.  Today, for a change, an inside day bereft of much volatility. Oops, wait. Not so much now i...

My Takeaways and Observations

Mr. Market has provided outstanding opportunities year to date. I am happy with the way I have been trading the market, taking advantage of the market without memory from day to day and staying with my game plan in an unemotional way. The banks -- e...

Takeaways and Observations

Hello, all -- I'm back! Great job yesterday by Chris "Not the Designer" Versace in subbing for me. My takeaways and observations regarding yesterday's action: St. Louis Fed President James Bullard is full of bull. Ray Dalio of hedge fund Bridgewater...

Biotech Breakout

Given my risk-averse profile, I made the unusual move last week of buying a basket of biotech stocks. And yesterday, I noted that Biotech Could Be Close to a 'Double Bottom': "I recently created a basket of a dozen speculative and conservative biote...

Biotech Goes From 'Zero' to 'Hero'

My basket of 12 biotech stocks is rocking this morning! We're seeing a 9% rally in Cempra (CEMP), a 5% rise in Intrexon (XON), a 4% gain in Acadia Pharmaceuticals (ACAD) and a 3% boost in Sage Therapeutics (SAGE).

My Takeaways and Observations

This might be the most hated market rally in months.  As I have been commenting, we got deeply oversold, support held and machines/algos did the rest! The typical correlation between SPDR S&P 500 ETF (SPY) and the inverse iShares 20+ Year Treasury B...

Today's Takeaways and Observations

Chuck (Judge Smails) thoroughly embarrassed me into making a day's end post, noting that when I was younger I had the energy to still complete Takeaways. He went on to write that my current age is slowing me down. I know (hope!) you were kidding and...

Buying Biotechs

The iShares Nasdaq Biotechnology ETF (IBB) has tumbled from nearly $400 a share early last summer to around $240 at last check, so I'm taking advantage of today's market schmeissing to purchase a small position in a biotech (biowreck?). I'm buying a...

Acadia upgraded at Piper

Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager

Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager

Unilever (UL) shares are up over 7% so far this year and the consumer staples giant will continue to perform well as it expands its reach in the emerging markets.

The Trader Daily: Let's Welcome Biotechs to the House of Pain

The bulls can show them around the place.

Buyers Get Back to Big-Caps

Market shows some love to overlooked groups.

Many Ways to Win

Try to find bullish charts that don't all look the same.

Acadia Is in a Holding Pattern

The stock has a mild downside bias, and its future direction will be influenced by IBB. By Ed Ponsi A reader asked about a specific biotech stock, so I'll handle that now. Biotechnology shares are in a tough area. Using the iShares Nasdaq Biotechnol...

Acadia's Allure

Let's take a peek at the daily and weekly charts. By Tim Collins Biotech has been scorching hot, so I'm always happy to get a request in the space. It is still the Wild West of trading with action almost on a daily basis. With only two eyes in my he...

Dr. Stockstalker

How I Learned to Stop Worrying and Love Market Correction.

More Meaningless Action

The danger is overacting when nothing much has changed.

Stick With the Long Side

Until there is a change in the price action, it's the best strategy.

Daily Recap of the Charts, July 19

Daily Recap of the Charts, July 19

John Darsie of T3Live review the day's market action and sets up your trading plan for the next session.

Morning Call, June 27

Morning Call, June 27

Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.

Stock-Picking Wins the Day

There's still speculative interest out there.

Hey 19

The Tuesday winning streak is more like your 19th nervous breakdown.

Slightly Negative but Still Frothy

A little weakness is actually good news.

Sailing on a Sea of Liquidity

If you don't accept it, you are going to have problems.